摘要
目的对脑苷肌肽和依达拉奉治疗急性缺血性脑卒中进行药物经济学评价。方法 88例急性缺血性脑卒中患者分为脑苷肌肽和依达拉奉两组进行成本分析。结果脑苷肌肽和依达拉奉组有效率分别为90.48%、89.13%,两组差异无统计学意义(P>0.05),每例患者的药费成本分别为4956.0元、4480元,两组差异无统计学意义(P>0.05)。结论从药物经济学角度分析,脑苷肌肽和依达拉奉疗效、成本均相当。
Objective To compare the cost-effectiveness of cattle encephalon glycoside and ignotin injection and edaravone injection schemes on acute isehemic stroke. Methods A total of 88 patients with acute ischemic stroke were ascribed to receive cattle encephalon glycoside and ignotin injection （scheme I）,edaravone injection （scheme II）,the cost-effectiveness analyses of 2 groups were conducted using pharmac, oeconomics method. Results The effective rates were 90.48%,89.13% respectively（P 〉 0.05）.The costs for the 2 schemes were 4956.0 and 4480.0 yuan,respectively.And the results were not significant between the two schemes（P 〉 0.05）. Conclusion From the point of view of pharmacoeconomics,the curative effect and cost of the two schemes are comparative.
出处
《中国医药科学》
2013年第6期44-45,共2页
China Medicine And Pharmacy
关键词
急性缺血性脑梗死
经济学评价
脑苷肌肽
依达拉奉
Acute ischemic stroke
Economic evaluation
Encephalon glycoside and ignotin
Edaravone
